cp wire

CP Wire Articles

Renovia Completes $42.3 Million Series B to Advance Pelvic Floor Treatment and Diagnostics
  • An estimated 250 million women worldwide are affected by urinary incontinence
  • Renovia currently has a product on the market to treat female urinary incontinence
  • The company... read more
Tue, 08/21/18 - 10:13 am
Allegro Appoints New CEO and Prepares for Ph III Trials for Diabetic Macular Edema Drug
  • New CEO Has 25 Years Experience in the ophthalmic pharmaceutical space
  • Luminate met primary endpoints in Ph IIb study
  • Luminate is a first-in-class integrin peptide therapy... read more
Tue, 08/21/18 - 09:55 am
Linzess Receives Additional Indication in Japan for Chronic Constipation



Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Ironwood Pharmaceuticals, Inc (Nasdaq: IRWD , “Ironwood”)  announced on 8/21/18 that approval... read more

Tue, 08/21/18 - 09:38 am
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria



Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced on 8/20/18 that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s Biologics License Application (BLA)... read more

Mon, 08/20/18 - 09:59 am
Aravive Biologics’ Treatment For Platinum-Resistant Recurrent Ovarian Cancer Receives Fast Track Designation
  • Ph I trial showed reduction in biomarker associated with anti-tumor activity in animal models
  • There were no serious or dose-limiting adverse events in the Ph I trial
  • Aravive... read more
Mon, 08/20/18 - 09:44 am

Pages